Current operating income before R&D slightly improving throughout first half of 2023 in percentage of revenue

In France and around the world, the medicalization of cats continues to progress, helping to increase their life expectancy. Two major pathologies affect these aging cats: chronic kidney disease and osteoarthritis. Specially adapted nutrition can help. That's why we're launching VETERINARY HPM^® Kidney & Joint in Europe in September. This new nutrition program enables the combined and gradual management of chronic kidney disease and osteoarthritis, thus improving the animal's quality of life. 

Following the decision of the board of directors on June 19, 2023 and its approval by the shareholder’s meeting, we are going to buy back 100,000 of our own shares (less than 1.25% of the capital). Main objective: to decrease the company's share capital by canceling treasury shares purchased.

At the end of August, with our priority systems fully restored and functional following the June cyberattack, we will be able to publish our mid-year results on September 28 with a two-week delay.

In June 2023, Virbac New Zealand celebrated 30 years of its commitment to animal health in Aotearoa New Zealand. All employees gathered together to mark this amazing achievement and look back on these past three decades.

Revenue up about 2% during the second quarter and stable at the end of June despite two unfavorable one-off effects throughout the semester

Last May, Virbac Japan employees gathered to celebrate the subsidiary's 30 years of commitment to animal health.

Virbac reassesses its 2023 growth and Adjusted EBIT¹ forecast

From July 2023, André Mathieu, appointed director of Virbac's Global Industrial operations, Supply chain & Sourcing since January 2, 2023, will join Virbac’s Group executive committee.

The Virbac Group was the target of a cyber attack on several of its sites worldwide during the night of June 19-20. 

Otitis externa is one of the main reasons why dogs visit the vet. Highly uncomfortable and painful for the animal, their treatment has until now involved the use of antibiotics in most of the cases. Starting this June, our teams are changing the way the disease is managed, by offering a Europe-wide antimicrobial-free solution, recommended as a first-line treatment in acute canine otitis externa where microbial overgrowth.

Virbac announces the appointment of Manuela Rodriguez as CSR director, effective April 3, 2023. Her main mission will be to develop and manage the Group's CSR strategy. 

Founded in 1983, Virbac Spain, one of the Group's oldest subsidiaries, celebrated 40 years of commitment to animal health on 11 May.

Atopic dermatitis is an inflammatory skin disease that affects 10% of dogs¹. Very disabling for the animal, it is also complex to diagnose and treat. To improve its management, our teams have developed DailyDerma: an innovative programme that brings together veterinarians and owners for better long-term management of the disease.

On May 2, we finalized the acquisition of 100% of the shares of our historical distributor in the Czech Republic and Slovakia, which becomes the 35^th Virbac subsidiary. Welcome!

In 2015, our Veterinary HPM^® dog and cat foods made their first appearance in Europe; they are now present in more than 30 countries worldwide. In 2023, we are continuing their development in Asia: after Japan, they have been available in India since last March, providing veterinarians and owners in the country with a preventive nutrition solution that contributes to the health of domestic carnivores.

On January 1, 2023, we finalized the creation of Virbac Ireland, our 34th subsidiary!

Slight decline in first-quarter revenue primarily due to a base effect as well as a context of market slowdown

Heartworm disease is a potentially fatal pathology affecting mostly dogs. Endemic to the Mediterranean basin, it appeared in Eastern Europe about ten years ago. Since February 2023, our teams have been offering veterinarians and owners in this region of the world a new, easy-to-use annual preventive solution to protect their pets effectively¹. 

Virbac announces Giovanni Abruzzini’s appointment as president and CEO of Virbac North America, effective March 27, 2023. His main mission is to lead and develop all North American Virbac activities, in line with our Group’s global strategy. 

2022 current operating income on the rise at +8.3%, reflecting the momentum of our business over the year in a slowing market

On February 21, our farm animals team organized a webinar attended by nearly 900 veterinarians from all over the world. The objective? To present our new Smart DCT tool, which allows a better assessment of the infectious pressure in dairy herds during the dry period. This action aims at supporting better adapted treatments and a more responsible use of antibiotics.

Rotavirus is one of the main agents causing diarrhea in piglets¹. Since December 2022, our teams have been providing industry professionals in France and Germany with the very first rotavirus vaccine registered for pigs, enabling the immunization of newborn piglets via their mother’s colostrum.

Annual revenue growth of +9.6% at comparable exchange rates and scope (+14.3% at real rates), driven by exceptional business activity in the fourth quarter

Discover the video on the 2023 wishes of Sébastien Huron to all the teams in the world.

In February 2022, Virbac Colombia celebrated its 20 years of commitment to animal health with all its employees and then, on November 4th, with the partners of its Colombian subsidiary and the Andean region, Sandrine Brunel as representative of the head office, the LatAm committee and the entire management team of Virbac Colombia & Andes.

On November 30, Virbac inaugurated its new R&D center in Pingtung Agricultural Biotechnology Park (PABP) in Taiwan which marked an important milestone for Virbac R&D.

Between May and June 2022, some thirty employees from each of our subsidiaries met for international Great Place To Work^® workshops to discuss the local employee experience and best practices within certified companies. 

Mobility issues are common in dogs and can greatly impact their quality of life. To keep their joints healthy, our teams have developed MOVOFLEX^®, a new joint supplement combining five ingredients, including eggshell membrane. It includes an innovative formulation, gradually available in Europe from November 2022, for a complete action that significantly contributes to improving the animal's mobility.